| 
				Shares of the company, which also runs drugstores, rose 2.4% in 
				early trading.
 CVS is moving deeper into healthcare and completed its Aetna 
				purchase last year, combining one of the largest pharmacy 
				benefit managers with one of the nation's oldest health 
				insurers.
 
 The pharmacy benefits management (PBM) business, which 
				negotiates discounts with drugmakers for its clients that 
				include insurers, gained in the third quarter from increased 
				pharmacy claims and a rise in prices of branded drugs.
 
 Sales in the unit rose 6.4% to $36.02 billion.
 
 The healthcare benefits business, which houses Aetna, reported 
				sales of $17.18 billion, helped by lower-than-expected medical 
				costs.
 
 The unit reported a medical benefit ratio of 83.3%, compared 
				with estimates of 84.3%, according to four analysts polled by 
				Refinitiv.
 
 The ratio is a key metric that compares the amount CVS spent on 
				medical claims with income from premiums.
 
 Even as the two businesses showed strength, CVS' retail unit 
				came under some pressure from lower reimbursement rates for 
				filing prescriptions, which has plagued the industry since the 
				past few quarters.
 
 CVS's rival drugstore chain Walgreen Boots Alliance Inc <WBA.O> 
				has been exploring whether to go private following private 
				equity interest in the company, Reuters reported on Tuesday, 
				citing sources.
 
 CVS said on Wednesday it plans to close 22 underperforming 
				retail pharmacy stores in the first quarter of 2020.
 
 Sales in CVS's retail unit rose 2.9% to 21.47 billion, the 
				slowest growth rate across its businesses in the quarter.
 
 The company now expects its 2019 adjusted profit to range 
				between $6.97 and $7.05 per share, compared with its previous 
				forecast of $6.89 to $7.00.
 
 CVS's net profit rose 10.1% to $1.53 billion, or $1.17 per 
				share, in the quarter ended Sept. 30.
 
 Excluding items, the company earned $1.84 per share, above 
				analysts' estimates of $1.77.
 
 Revenue jumped 36.5% to $64.81 billion, beating the average 
				analyst estimate of $62.99 billion.
 
 (Reporting by Manas Mishra and Trisha Roy in Bengaluru; Editing 
				by Maju Samuel)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
				 
				  |  |